Sitagliptin (Januvia™) is a new oral agent approved by the US FDA ... the primary enzyme degrading the incretin hormones, allowing glucagon-like peptide-1 and glucose-dependent insulinotropic ...

HS-10535 is a glucagon-like peptide (GLP)-1 analog under development as an oral medication, similar to Novo Nordisk's Wigov. Merck is also collaborating with another Chinese corporation to license an ...

ORLANDO, FLA. — Increasing levels of protein and fiber, stressing portion control and adding savory flavors are ways that ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

Glucagon-like peptide-1 (GLP-1) is a well-known medication used by physicians to treat Type 2 diabetes. GLP-1 has also become ...

Is insurance coverage of pricey glucagon-like peptide 1 (GLP-1) receptor agonists for obesity about to increase dramatically? Advocates of the anti-obesity medications are hopeful, especially if ...

They work by mimicking the action of a hormone called glucagon-like peptide 1 (hence GLP-1), stimulating the body to produce more insulin and decreasing blood sugar spikes by slowing digestion.

“There’s a lot of hype and excitement around GLP-1 and like medications,” Youssef. “And the thing I want to see is long-term safety data. Whenever we give medication to a large portion of ...

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...